Glaukos Corporation, a pioneering force in the ophthalmic industry, is headquartered in the United States, with significant operations across North America and Europe. Founded in 1998, Glaukos has established itself as a leader in developing innovative therapies for glaucoma and other eye diseases. The company is renowned for its unique micro-invasive surgical procedures, particularly the iStent® technology, which has transformed the treatment landscape for patients suffering from glaucoma.
With a commitment to advancing eye care, Glaukos has achieved notable milestones, including the first FDA approval of a micro-invasive glaucoma surgery device. The company’s dedication to research and development has positioned it at the forefront of the ophthalmic market, making significant contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
+5 vs industry average
Glaukos’s score of 27 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Glaukos?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Health Services has typical carbon intensity
Industry performance
The Health Services industry has increased its overall emissions by 7% since 2019
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Glaukos's reported carbon emissions
In 2024, Glaukos Corporation reported total emissions of approximately 3,086,600 kg CO2e, comprising 523,300 kg CO2e from Scope 1 and 2,533,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions to near zero by 2025. This target reflects Glaukos's dedication to sustainability and aligns with industry standards for climate action. Over the previous year, 2023, Glaukos's emissions were approximately 2,715,800 kg CO2e, with Scope 1 emissions at 575,400 kg CO2e and Scope 2 emissions at 2,159,400 kg CO2e. The company has consistently reported emissions data for Scope 1 and 2 but has not disclosed any Scope 3 emissions, indicating a focus on direct and indirect operational emissions. Glaukos's commitment to reducing emissions is part of a broader trend within the medical technology industry, where companies are increasingly prioritising sustainability and climate responsibility. The company's initiatives are documented in their sustainability reports, showcasing their progress and future goals in addressing climate change.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Glaukos’s Climate Goals (2030 & 2050)
2 goals2025
We aim to reduce our Scope 1 and 2 emissions to near zero by…
We aim to reduce our Scope 1 and 2 emissions to near zero by the middle of this decade.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Glaukos
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project